In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company. Dendreon discussed the NCA, as well as early sales for the autologous immunotherapy, during its second quarter earnings call Aug. 3. Reimbursement decisions for the physician-infused product are being watched carefully by investors since Provenge...